Female Pelvic Med Reconstr Surg. 2017 Jul/Aug;23(4):228-231. doi: 10.1097/SPV.0000000000000432.
Asymptomatic microscopic hematuria is an important clinical sign of urinary tract malignancy. Asymptomatic microscopic hematuria has been variably defined over the years. In addition, the evidence primarily is based on data from male patients. However, whether the patient is a man or a woman influences the differential diagnosis of asymptomatic microscopic hematuria, and the risk of urinary tract malignancy (bladder, ureter, and kidney) is significantly less in women than in men. Among women, being older than 60 years, having a history of smoking, and having gross hematuria are the strongest predictors of urologic cancer. In low-risk, never-smoking women younger than 50 years without gross hematuria and with fewer than 25 red blood cells per high-power field, the risk of urinary tract malignancy is less than or equal to 0.5%. Furthermore, the evaluation may result in more harm than benefit and is unlikely to be cost effective. Thus, data support changing current hematuria recommendations in this low-risk group. The American College of Obstetricians and Gynecologists and the American Urogynecologic Society encourage organizations producing future guidelines on the evaluation of microscopic hematuria to perform sex-specific analysis of the data and produce practical sex-specific recommendations. In the meantime, the American College of Obstetricians and Gynecologists and the American Urogynecologic Society recommend that asymptomatic, low-risk, never-smoking women aged 35-50 years undergo evaluation only if they have more than 25 red blood cells per high-power field.
无症状镜下血尿是泌尿系统恶性肿瘤的重要临床体征。多年来,无症状镜下血尿的定义一直存在差异。此外,证据主要基于男性患者的数据。然而,患者是男性还是女性会影响无症状镜下血尿的鉴别诊断,而且女性患泌尿系统恶性肿瘤(膀胱、输尿管和肾脏)的风险明显低于男性。在女性中,年龄大于60岁、有吸烟史和肉眼血尿是泌尿系统癌症最强的预测因素。在低风险、从不吸烟、年龄小于50岁、无肉眼血尿且每高倍视野红细胞少于25个的女性中,泌尿系统恶性肿瘤的风险小于或等于0.5%。此外,评估可能弊大于利,而且不太可能具有成本效益。因此,数据支持改变对这一低风险群体目前的血尿评估建议。美国妇产科医师学会和美国妇科学会鼓励未来制定镜下血尿评估指南的组织对数据进行针对性别的分析,并提出切实可行的针对性别的建议。同时,美国妇产科医师学会和美国妇科学会建议,35至50岁无症状、低风险、从不吸烟的女性,只有在每高倍视野红细胞超过25个时才进行评估。